InvestSMART

Cyclopharm Limited (ASX:CYC)

ALERT: Price-sensitive ASX Announcement for CYC
Current share price for CYC : $0.360 -0.16 (-30.77%)+
Announcement
Release
29 Jul 2026 8:31AM
Price at Release
$0.520
Full Release
download
Summary
Cyclopharm Limited announced that new US lung imaging guidelines have named their product, Technegas®, as the preferred ventilation agent. This comes as the first update in 14 years, published by leading nuclear medicine societies. The guidelines highlight the advantages of Technegas® in terms of lower radiation doses compared to CT pulmonary angiograms and endorse the use of three-dimensional imaging techniques. These guidelines could drive broader adoption of Technegas® in the US, expanding its use beyond pulmonary embolism diagnosis to other conditions such as chronic pulmonary issues and lung function assessments. The company anticipates that these enhancements will accelerate clinical demand and utilization of Technegas® in the US market.
Key Points
  • Technegas® named as the preferred ventilation agent in new US lung imaging guidelines.
  • New guidelines published by four international nuclear medicine societies.
  • The guidelines endorse three-dimensional imaging techniques beneficial for Technegas®.
  • Technegas® offers a lower radiation dose compared to CT pulmonary angiogram.
  • Guidelines expand the use of Technegas® beyond pulmonary embolism diagnosis.
  • Cyclopharm sees potential for increased adoption of Technegas® in US hospitals.
  • Technegas® data supports artificial intelligence applications in lung imaging.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.